CARLSBAD, Calif., May 03, 2018 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today financial results for the quarter ended March 31, 2018.
Summary First Quarter 2018 Financial Results and Recent Accomplishments
- Revenue of $33.2 million, an increase of 4.0% year-over-year
- U.S. revenue of $29.5 million, an increase of 3.2% year-over-year
- U.S. Orthobiologics revenue of $15.8 million, a 4.9% increase year-over-year
- U.S. Spinal Implants revenue of $13.7 million, a 1.4% increase year-over-year
- International revenue of $3.6 million, an increase of 10.8% year-over-year
- Transitioned OsteoBallast™ Demineralized Bone Matrix in Resorbable Mesh to full commercial launch
“We are pleased with our first quarter results, which reflect solid revenue growth in both our Orthobiologics and Spinal Implants portfolios, as well as operational efficiencies,” said Keith Valentine, President and Chief Executive Officer. “As we continue to upgrade our distribution footprint, we are well positioned to leverage our recently launched products and development pipeline across both franchises to deliver clinical value to surgeons, hospitals, and patients.”
First Quarter 2018 Financial Results
Total revenue for the first quarter of 2018 was $33.2 million, a 4.0% increase compared to the same period of the prior year. Total U.S. revenue was $29.5 million, a 3.2% increase compared to the same period of the prior year.
Orthobiologics revenue totaled $18.0 million, a 5.2% increase compared to the first quarter of 2017, and was led by growth in our DBM franchise. Spinal Implants revenue totaled $15.2 million, a 2.6% increase compared to the first quarter of 2017, and was driven by growth in the Shoreline and Mariner systems.
Gross margin for the first quarter of 2018 was 63.3%, compared to 58.7% for the same period in 2017. The increase was primarily driven by lower raw material and manufacturing costs for orthobiologics products manufactured at the Company’s Irvine, California facility.
Operating expenses for the first quarter of 2018 totaled $28.0 million, compared to $27.8 million for the same period of the prior year. The $0.2 million increase in operating expenses was driven by higher selling and marketing expenses, partially offset by lower R&D and general and administrative expenses.
Net loss for the first quarter of 2018 was $7.1 million, compared to a net loss of $9.1 million for the same period of the prior year.
Cash and cash equivalents at March 31, 2018 totaled $12.5 million and the Company had no outstanding borrowings against its $30 million credit facility. The Company realized $8.5 million in net proceeds in the first quarter of 2018 through the sale of its common stock under its “at the market” equity offering program.
2018 Financial Outlook
SeaSpine reiterates expectations for full-year 2018 revenue to be in the range of $135 to $139 million, reflecting growth of 2.5% to 5.5% over full-year 2017 revenue.
Webcast and Conference Call Information
The Company’s management team will host a conference call beginning today at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments. Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 8167947. To listen to the webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.
The call will be archived until Thursday May 17, 2018. The audio archive can be accessed by calling (855) 859-2056 in the U.S. or (404) 537-3406 from outside the U.S. The passcode for the audio replay is 8167947.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete procedural solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Forward-Looking Statements
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the Company’s expectations to leverage recently launched products and development pipeline to deliver clinical value; and the Company’s expectations for full-year 2018 revenue. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: surgeons’ willingness to continue to use the Company’s existing products and to adopt its newly launched products, including the risk that the Company’s products do not demonstrate adequate safety or efficacy, independently or relative to competitive products, to support expected levels of demand or pricing; the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of clinical validation of products in limited commercial (or “alpha”) launch; the Company’s ability to attract new, high-quality distributors, whether as a result of inability to reach agreement on financial or other contractual terms or otherwise, disruption to the Company’s existing distribution network as new distributors are added, and the ability of new distributors to generate growth or offset disruption to existing distributors; continued pricing pressure, whether as a result of consolidation in hospital systems, competitors or others, as well as exclusion from major healthcare systems, whether as a result of unwillingness to provide required pricing or otherwise; the risk of supply shortages and the associated, potentially long-term disruption to product sales, including as a result of the Company’s dependence on a limited number of third-party suppliers for components and raw materials, or otherwise; unexpected expense and delay, including as a result of developing and supporting the launch of new products, the fact that newly launched products may require substantial additional development activities, which could introduce further expense and delay, or as a result of obtaining regulatory clearances; the Company’s ability to continue to invest in medical education and training, product development, and/or sales and marketing initiatives at levels sufficient to drive future revenue growth, including as a result of its inability to obtain funding on a timely basis on acceptable terms, or at all; general economic and business conditions in the markets in which the Company does business, both in the U.S. and abroad; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact
Lynn Pieper
(415) 937-5405
ir@seaspine.com
SEASPINE HOLDINGS CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
| Three Months Ended March 31, | |||||||
| 2018 | 2017 | ||||||
| Total revenue, net | $ | 33,175 | $ | 31,894 | |||
| Cost of goods sold | 12,179 | 13,172 | |||||
| Gross profit | 20,996 | 18,722 | |||||
| Operating expenses: | |||||||
| Selling, general and administrative | 24,467 | 23,970 | |||||
| Research and development | 2,789 | 3,050 | |||||
| Intangible amortization | 792 | 792 | |||||
| Total operating expenses | 28,048 | 27,812 | |||||
| Operating loss | (7,052 | ) | (9,090 | ) | |||
| Other income (expense), net | 20 | (13 | ) | ||||
| Loss before income taxes | (7,032 | ) | (9,103 | ) | |||
| Provision for income taxes | 73 | — | |||||
| Net loss | $ | (7,105 | ) | $ | (9,103 | ) | |
| Net loss per share, basic and diluted | $ | (0.50 | ) | $ | (0.79 | ) | |
| Weighted average shares used to compute basic and diluted net loss per share | 14,085 | 11,586 | |||||
SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(In thousands)
| March 31, 2018 |
December 31, 2017 |
||||||
| (unaudited) | |||||||
| Cash and cash equivalents | $ | 12,470 | $ | 10,788 | |||
| Trade accounts receivable, net of allowances of $492 and $466 | 20,639 | 21,872 | |||||
| Inventories | 43,285 | 41,721 | |||||
| Short-term debt | — | — | |||||
| Total current liabilities | 21,445 | 23,157 | |||||
| Long-term borrowings under credit facility | — | — | |||||
| Total stockholders’ equity | 107,625 | 105,653 | |||||
